Nektar Therapeutics reports Q4 net income $7.3M; rezpegaldesleukin Phase 2b data expected in 2025

NEKTAR THERAPEUTICS

Q4 net income $7.3M ($0.03 EPS) vs net loss $42.1M in Q4 2023; full year net loss $119M vs $276.1M.
Revenue Q4 $29.2M (+22% YoY); cash $269.1M, expected to fund operations into Q4 2026.
Rezpegaldesleukin Phase 2b topline data: atopic dermatitis in Q2 2025, alopecia areata in Q4 2025.
FDA granted Fast Track designation for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
Sold PEGylation manufacturing business for $90M enterprise value ($70M cash + $20M equity).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.